Lilly is considering expanding the availability of lower-priced vials of its blockbuster obesity drug Zepbound ...

The company anticipates 2025 revenue to be in the range of $58.0 billion to $61.0 billion, growth of 32% at the midpoint compared to expected 2024 revenue ...

The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...

Nicole Albanese, PharmD, discusses the science behind weight-loss drugs, their potential to treat other addictions as well as ...

Eli Lilly and Company (LLY) is a global leader in healthcare innovation, specializing in discovering, developing, and ...

The U.S. FDA has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea.

LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, ...

We believe VK2735's clinical results to-date suggest a differentiated profile ... Forward-Looking Statements This press release contains forward-looking statements regarding Viking Therapeutics, Inc., ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Sleep apnea causes people to stop and start breathing repeatedly Zepbound is first drug approved by FDA to help treat it Two studies found that those who used it saw reduction in apnea events ...

Also Read: BookMyShow 2024 throwback report: RECORD 2.3 million tickets sold on Singham Again and Bhool Bhulaiyaa 3’s release date; 10.8 lakh people saw Pushpa 2 alone; Kalki 2898 AD ...